依折麦布联合瑞舒伐他汀对急性心肌梗死PCI术后患者血脂及心血管不良事件发生情况的影响  

Effects of ezetimibe combined with rosuvastatin on blood lipid and the occurrence of cardiovascular adverse events in patients with acute myocardial infarction after PCI

作　　者：张振岭 刘利月 蒲大伟 黄国涛[1] 郭军霞[1] 张俊彪[1] 刘辉[1] ZHANG Zhenling;LIU Liyue;PU Dawei;HUANG Guotao;GUO Junxia;ZHANG Junbiao;LIU Hui(No.2 Cardiovascular Internal Medicine Department,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Pharmacy Department,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院心血管内二科,河南新乡453100 [2]新乡医学院第一附属医院药学部,河南新乡453100

出　　处：《临床医学研究与实践》2025年第4期62-65,共4页Clinical Research and Practice

摘　　要：目的 探讨依折麦布联合瑞舒伐他汀对急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)术后患者血脂及心血管不良事件发生情况的影响。方法 选取2020年1月至10月于心血管内科住院并行PCI术治疗的96例AMI患者为研究对象,将其随机分为对照组和观察组,每组48例。两组均接受常规药物治疗,对照组给予瑞舒伐他汀治疗,观察组在对照组基础上加用依折麦布治疗。比较两组的治疗效果。结果 治疗后,观察组的6 min步行试验距离长于对照组,左心室射血分数(LVEF)高于对照组(P<0.05)。治疗1、3、6个月后,两组的总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)水平均低于治疗前,高密度脂蛋白胆固醇(HDL-C)水平均高于治疗前(P<0.05);治疗1、3、6个月后,观察组的TC、TG及LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。观察组的心血管不良事件总发生率低于对照组(P<0.05)。结论 依折麦布联合瑞舒伐他汀用于AMI患者PCI术后可有效调节血脂指标水平,改善心功能,降低心血管不良事件发生风险,值得在临床中推广及应用。Objective To investigate the effects of ezetimibe combined with rosuvastatin on blood lipid and the occurrence of cardiovascular adverse events in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods A total of 96 patients with AMI who were hospitalized in the cardiovascular internal medicine department and treated with PCI from January to October 2020 were selected as the research objects,and the patients were randomly divided into control group and observation group,with 48 cases in each group.Both groups were treated with conventional drugs,the control group was treated with rosuvastatin,and the observation group was treated with ezetimibe on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the distance of 6 min walking test in the observation group was longer than that in the control group,and the left ventricular ejection fraction(LVEF)was higher than that in the control group(P<0.05).After 1,3 and 6 months of treatment,the levels of total cholesterol(TC),triglyceride(TG)and low density lipoprotein-cholesterol(LDL-C)in the two groups were lower than those before treatment,and the level of high density lipoprotein-cholesterol(HDL-C)was higher than that before treatment(P<0.05);after 1,3 and 6 months of treatment,the levels of TC,TG and LDL-C in the observation group were lower than those in the control group,and the level of HDL-C was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The total incidence of cardiovascular adverse events in the observation group was lower than that in the control group(P<0.05).Conclusion Ezetimibe combined with rosuvastatin can effectively regulate the levels of blood lipid indexes,improve cardiac function and reduce the risk of cardiovascular adverse events in patients with AMI after PCI,which is worthy of promotion and application in clinical practice.

关 键 词：急性心肌梗死 经皮冠状动脉介入治疗 依折麦布 瑞舒伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病]